Venus Remedies secures Saudi FDA approval for the oncology drug Plerixafor, marking their first global authorization for cancer treatments. This approval allows them to commercialize the drug in Saudi Arabia, targeting its burgeoning oncology market and advanced stem cell facilities.

Venus Remedies will discuss their financial results for the fiscal year 2026, dividends, and annual general meeting matters at a board meeting scheduled for May 26th, 2026. The trading window has been closed since April 1st, 2026.

Venus Remedies Ltd plummets by 5%, freezing its stock price at ₹949.60, with no buyers in sight, indicative of an unfavorable supply-demand dynamic.

Venus Remedies Ltd reached an all-time high of Rs 947 on April 8, 2026, marking a significant recovery from its initial modest gap down.

Venus Remedies has experienced a cup-and-handle breakout, indicating a potential price increase due to growing bullish sentiment, as demonstrated by the surge in trading volume and consecutive highs over the past week.